Neuroendocrine Differentiated Breast Cancer Cases: A Retrospective Analysis and Literature Review

Conclusion: NEBC is a subtype that is both histopathologically and radiologically distinct from other breast cancer subtypes, and neuroendocrine differentiation may be an important predictive marker in the future.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Objectives: Neuroendocrine breast carcinoma (NEBC) is a rare subgroup of breast cancer, which makes up 2–5% of all invasive breast cancers.

📊

Key Findings & Data:Methods: We retrospectively analyzed clinical, pathological, and radiological characteristics of 36 patients diagnosed with neuroendocrine differentiated breast cancer between 2008 and 2019 compared to that of 925 patients with invasive ductal carcinoma (IDC/NOS) along with a literature review.

💡

Conclusion & Impact:Conclusion: NEBC is a subtype that is both histopathologically and radiologically distinct from other breast cancer subtypes, and neuroendocrine differentiation may be an important predictive marker in the future.

🔬Design:Review & Systematic Survey

📍Scope:2008 Verileri

⚙️Variables:Domain Parameters

Özet

Objectives: Neuroendocrine breast carcinoma (NEBC) is a rare subgroup of breast cancer, which makes up 2–5% of all invasive breast cancers. The aim of this retrospective analysis is to present and analyze our own data of primary NEBCs. Methods: We retrospectively analyzed clinical, pathological, and radiological characteristics of 36 patients diagnosed with neuroendocrine differentiated breast cancer between 2008 and 2019 compared to that of 925 patients with invasive ductal carcinoma (IDC/NOS) along with a literature review. Results: In this study, 36 patients with neuroendocrine differentiated breast carcinoma and 961 patients with (IDC/NOS), as the comparison group, were identified between 2008 and 2019. In NEBC patients, seven were premenopausal and 29 postmenopausal. Patients whose ultrasound (USG), magnetic resonance, and mammographic (MMG) images available in our hospital, high-density masses were detected in the MMG with irregular (77%), microlobulated (80%) and spiculated margins (63%), unaccompanied by asymmetry and structural distortion. Calcifications were less common than invasive breast cancer, present only in four patients (17%). When NEBC were compared to ductal carcinomas (n=925), NEBC were more often human epidermal growth factor receptor 2 negative (p=0.039), estrogen receptor positive (p=0.05), progesterone receptor positive (0.03), and the NEBC patients were older (p=0.02). Age, grade, metastatic status, lymph node number, and molecular type were identified as prognostic factors that significantly affect survival in both groups (p<0.05). Conclusion: NEBC is a subtype that is both histopathologically and radiologically distinct from other breast cancer subtypes, and neuroendocrine differentiation may be an important predictive marker in the future.

🔖

Cite This Article

ÖZDEMİR, Ö., YILDIZ, Y., YİLDİZ, Y., SARAY, S., ALACACIOĞLU, A., TAŞLI, F., ERDİ, Z. C., TAŞKAYNATAN, H., VAROL, U., ADIBELLİ, Z., ONMUŞ, İ. R. D., KÜÇÜKZEYBEK, Y. (2021). Neuroendocrine Differentiated Breast Cancer Cases: A Retrospective Analysis and Literature Review. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 55 - Sayı: 4, [503]–509. https://ajindex.com/articles/399592

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (15)

Mjønes P, Sagatun L, Nordrum IS, Waldum HL. Neuron-specific enolase as an immunohistochemical marker is better than its reputation. J Histochem Cytochem 2017;65:687–703
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO classifcation of tumours of the breast - vol 4. 4th ed. Lyon: International Agency for Research on Cancer; 2012
Woodard BH, Eisenbarth G, Wallace NR, Mossler JA, McCarty KS Jr. Adrenocorticotropin production by a mammary carcinoma. Cancer 1981;47:1823–7
Klöppel G. Neuroendocrine neoplasms: dichotomy, origin and classifications. Visc Med 2017;33:324–30
Modlin IM, Shapiro MD, Kidd M. An analysis of rare carcinoid tumors: clarifying these clinical conundrums. World J Surg 2005;29:92–101
Kawasaki T, Kondo T, Nakazawa T, Mochizuki K, Yamane T, Murata S, et al. Is CD56 a specific and reliable neuroendocrine marker for discriminating between endocrine/neuroendocrine ductal carcinoma in situ and intraductal papilloma of the breast? Pathol Int 2011;61:49–51
Cloyd JM, Yang RL, Allison KH, Norton JA, Hernandez-Boussard T, Wapnir IL. Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast. Breast Cancer Res Treat 2014;148:637–44
Adams RW, Dyson P, Barthelmes L. Neuroendocrine breast tumours: breast cancer or neuroendocrine cancer presenting in the breast? Breast 2014;23:120–7
Feyrter F, Hartmann G. On the carcinoid growth form of the carcinoma mammae, especially the carcinoma solidum (gelatinosum) MAMMAE. [Article in German]. Frankf Z Pathol 1963;73:24– 39
Cubilla AL, Woodruff JM. Primary carcinoid tumor of the breast. A report of 8 patients. Am J Surg Pathol 1977;1:283–92
Pülat H, Sabuncuoğlu MZ, Karaköse O, Benzin MF, Eroğlu HE, Kemal Kürşat Bozkurt KKB. A rare breast tumor: primary neuroendocrine carcinoma. Turk J Surg 2018;35:236–40
Wang J, Wei B, Albarracin CT, Hu J, Abraham SC, Wu Y. Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database. BMC Cancer 2014;14:147
Kim JE, Kim JY, Kim SH, Bae KE, Le JH, Kang MJ, et al. Primary breast carcinoma with neuroendocrine features: Imaging features on mammography and ultrasonography. J Korean Soc Radiol 2019;80:129–34
Jeon CH, Kim SM, Jang M, Yun BL, Ahn HS, Kim SW, et al. Clinical and radiologic features of neuroendocrine breast carcinomas. J Ultrasound Med 2014;33:1511–8
Giovanella L, Marelli M, Ceriani L,